**Conference:** Society for Epidemiologic Research Annual Meeting

**Location:** Austin, Texas

**Dates:** 6/18/2024-6/21/2024

**Deadline:** 1/14/2024

**Title:** Determinants of Hepatitis C Virus Treatment Completion Among Los Angeles County Residents Diagnosed Between January 1, 2021 and April 30, 2022

**Authors:** Cassidy Hernandez-Tamayo1, Chrysovalantis Stafylis1, Albert J Farias1, Lokesh Bhardwaj1, Riya Shah1, Tatiana Becerra1, Dara Bruce1, Roopkamal Saini1, Natalie Saremi1, Immanuel Thomas1, Krzel Manansala-Tan1, Arjun Vij1, Alison Li1, Nathan Sudeep1, Jacob Gizamba1, Bijan Hosseini1, Sabrina Navarro1, Sofia Ufret-Rivera1, Gilbert Orta Portillo1, Prabhu Gounder2, Mirna Ponce Jewell2, Jeffrey D Klausner1

**Affiliations**

1 Department of Population and Public Health Sciences, University of Southern California, Los Angeles

2 Los Angeles County Department of Public Health, Acute Communicable Disease Control, Viral Hepatitis Unit, Los Angeles

**Submitting Author Email:** [cassidyj@usc.edu](mailto:cassidyj@usc.edu)

**Submitting Author Affiliation:** Department of Population and Public Health Sciences, University of Southern California, Los Angeles

**Status of Submitting Author:** Student/Post-Doc

**Presenting Author Name:** Cassidy Hernandez-Tamayo

**Presenting Author Email:** [cassidyj@usc.edu](mailto:cassidyj@usc.edu)

**Presenting Author Affiliation:** Department of Population and Public Health Sciences, University of Southern California, Los Angeles

**Character Count:** 2000 characters, including spaces

**Primary Category:** Infectious Disease

**Secondary Category:** Health Disparities

**Background:** Hepatitis C Virus (HCV) infection is a treatable leading cause of death in the United States. However, there is little population-based evidence to establish determinants of treatment completion. Thus, we undertook an observational study of recently reported cases and treatment outcomes in Los Angeles (LA) County.

**Methods:** We identified residents with a reported positive HCV RNA test result in the LA County registry from January 2021 to April 2022. We interviewed cases about their HCV infection awareness and treatment status. We evaluated bivariate and multivariable associations between demographics and clinical characteristics and treatment completion using Pearson’s Chi-Square Tests and multivariable logistic regression, respectively. Prevalence odds ratios and 95% confidence intervals determined the magnitude of the multivariable associations.

**Results:** Among 611 cases interviewed, the majority were publicly insured (61%), male (65%), and untreated (72%). There were no statistically significant differences in the proportion of untreated respondents in the minority compared to non-minority groups (75% vs 70%, p=0.20). However, Black individuals compared to other ethnic groups had the highest proportion of untreated respondents (77%, p=0.04). A higher proportion of symptomatic compared to asymptomatic respondents were untreated (87% vs 61%, p<0.01). In the multivariable model, Black respondents had 0.4 (95% CI: 0.2, 0.8) times the odds of completing treatment compared to Whites. Asymptomatic respondents had 4.4 (95% CI: 2.3, 8.4) times the odds of completing treatment compared to those symptomatic, adjusted for liver disease diagnosis, insurance status, provider type, heritage and age group.

**Conclusion:** Respondents who were Black and symptomatic compared to those White and asymptomatic were less likely to be treated. Low treatment completion rates suggest the need to establish expanded public health efforts to ensure timely treatment in these populations.

1998/2000 with spaces